Mesoblast Limited (MESO) NASDAQ

14.52

-0.34(-2.29%)

Updated at June 02 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Silviu Itescu FACP FACRA FRACP MBBS	Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director	1.73M	1957
Paul J. Simmons	Scientific Advisor to the Chief Executive Officer	0	1959
Eric A. Rose	Chief Medical Officer & Executive Director	916,918	1951
Fiona See	Senior Vice President & Head of Translational Research	0	N/A
Daniel Devine	Head of Special Projects	0	N/A
James Michael O'Brien	Chief Financial Officer	0	1966
Justin Horst	Head of Manufacturing	0	N/A
Marcelo Santoro	Chief Commercial Officer	0	N/A
Paul Hughes BPHARM	Global Head of Corporate Communications & Joint Company Secretary	0	N/A
Peter T. Howard	General Counsel & Corporate Executive	0	1968
Geraldine Storton	Head of Regulatory Affairs & Quality Management	0	N/A

Name

Title

Pay

Year Born

Silviu Itescu FACP FACRA FRACP MBBS

Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director

1.73M

1957

Paul J. Simmons

Scientific Advisor to the Chief Executive Officer

1959

Eric A. Rose

Chief Medical Officer & Executive Director

916,918

1951

Fiona See

Senior Vice President & Head of Translational Research

N/A

Daniel Devine

Head of Special Projects

N/A

James Michael O'Brien

Chief Financial Officer

1966

Justin Horst

Head of Manufacturing

N/A

Marcelo Santoro

Chief Commercial Officer

N/A

Paul Hughes BPHARM

Global Head of Corporate Communications & Joint Company Secretary

N/A

Peter T. Howard

General Counsel & Corporate Executive

1968

Geraldine Storton

Head of Regulatory Affairs & Quality Management

N/A

Description

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.